Biopropello: olive-leaf derived biostimulant enhancing agricultural sustainability
BioPropello is an innovative biostimulant derived from olive leaves that increases crop performance by enhancing nutrient uptake and resilience. It synergistically improves the efficacy of Valent's pesticide formulations and is suitable for drone-based applications.
Overview
BioPropello is a cutting-edge biostimulant developed from olive leaf waste, designed to enhance agricultural productivity sustainably. This water-soluble powder has been proven to increase nutrient uptake, boost protein levels, and improve plant resilience to abiotic stress. By integrating with Valent's pesticide formulations, BioPropello ensures greater synergy and efficacy, particularly in ultra-low-volume applications such as drone-based delivery. Existing GRAS, EFSA, and Health Canada approvals streamline its integration into current agricultural practices, offering a scalable solution to meet global food production demands.
Technical specifications
Key features:
- Water-soluble formulation: Ensures easy application and adaptability for various delivery methods, including drone technologies.
- Crop performance enhancement: Demonstrated a 75% increase in germination rates and a 49% growth increase in rice within 28 days.
- Synergy with pesticides: Enhances the effectiveness of Valent’s pesticide formulations, contributing to improved agricultural sustainability.
- Regulatory compliance: Holds GRAS, EFSA, and Health Canada approvals, facilitating integration and reducing regulatory hurdles.
Technology readiness level
BioPropello is currently at Technology Readiness Level 5, having demonstrated its efficacy and compatibility in laboratory and greenhouse settings. Ongoing and future trials aim to validate its performance in broader field applications, optimize formulation scalability, and ensure regulatory alignment with EPA guidelines.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Industry applications
delivered to your inbox.